Cargando…

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report

Osimertinib, a third-generation tyrosine kinase inhibitor, is the first-line treatment for metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor (EGFR) mutations. It is known to cause drug-induced cardiotoxicity, including QT prolongation syndrome, heart fai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saito, Zentaro, Imakita, Takuma, Ito, Takanori, Oi, Issei, Kanai, Osamu, Fujita, Kohei, Tachibana, Hiromasa, Mio, Tadashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601787/ https://www.ncbi.nlm.nih.gov/pubmed/37900846 http://dx.doi.org/10.1159/000533826

Ejemplares similares

Safety and Efficacy of Flexible Bronchoscopy in Elderly Patients: A Retrospective Comparative Study
por: Saito, Zentaro, et al.
Publicado: (2023)

Pegfilgrastim-Induced Aortitis in a Patient with Small-Cell Lung Cancer Who Received Immunotherapy Combined with Chemotherapy
por: Ito, Takanori, et al.
Publicado: (2023)

A 92‐year‐old patient with thoracic empyema successfully treated by CT‐guided insertion of a pigtail catheter
por: Fujita, Kohei, et al.
Publicado: (2023)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

Re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients previously treated with anti-programmed death-1 and/or anti-programmed death ligand-1 antibodies
por: Imakita, Takuma, et al.
Publicado: (2023)

Simultaneous regression of non‐small cell lung cancer and orbital extranodal marginal zone lymphoma with chemoradiotherapy for lung cancer
por: Oi, Issei, et al.
Publicado: (2023)

Comparison of frailty in patients with nontuberculous mycobacterial lung disease and bronchiectasis: a prospective cohort study
por: Fujita, Kohei, et al.
Publicado: (2022)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Impact of the COVID-19 pandemic on the trajectory of the number of bronchoscopies performed in a tertiary hospital in Kyoto city
por: Fujita, Kohei, et al.
Publicado: (2023)

Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies
por: Bickert, Christiane, et al.
Publicado: (2021)

Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report
por: Sato, Yozo, et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient
por: Fujita, Kohei, et al.
Publicado: (2022)

Successful Rechallenge with Osimertinib after Very Acute Onset of Drug-Induced Pneumonitis
por: Mohammed, Turab, et al.
Publicado: (2021)

Pulmonary Lymphangitis Carcinomatosa Mimicking Immunotherapy-Related Interstitial Pneumonitis: A Case Report
por: Imakita, Takuma, et al.
Publicado: (2022)

Impact of COVID‐19 pandemic on lung cancer treatment scheduling
por: Fujita, Kohei, et al.
Publicado: (2020)

Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
por: Imakita, Takuma, et al.
Publicado: (2017)

Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
por: Mamesaya, Nobuaki, et al.
Publicado: (2017)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
por: Harada, Guilherme, et al.
Publicado: (2019)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Pleural involvement of diffuse large B-cell lymphoma mimicking malignant pleural mesothelioma
por: Ito, Takanori, et al.
Publicado: (2020)

Small cell transformation of non‐small cell lung cancer under immunotherapy: Case series and literature review
por: Imakita, Takuma, et al.
Publicado: (2021)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non‐small cell lung cancer
por: Kanai, Osamu, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021)

Successful Management of Osimertinib-Induced Heart Failure
por: Fukuo, Atsuko, et al.
Publicado: (2022)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
por: Shiroyama, Takayuki, et al.
Publicado: (2016)

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab
por: Lopez, Michael, et al.
Publicado: (2023)

Successful management of a lung cancer patient harbouring both EGFR mutation and EML4-ALK fusion gene with disseminated intravascular coagulation
por: Fujita, Kohei, et al.
Publicado: (2021)

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

Finding chinks in the osimertinib resistance armor
por: Leal, Jose Luis, et al.
Publicado: (2020)

Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib
por: Yanagisawa, Atsushi, et al.
Publicado: (2022)

Decreased handgrip strength can predict lung function impairment in male workers: a cross sectional study
por: Kanai, Makiko, et al.
Publicado: (2020)

Osimertinib induced cardiomyopathy: A case report
por: Shinomiya, Shun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6enhfu551gb9gvjtrtrsbfdnqr